九州通医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 证券代码：600998 证券简称：九州通 公告编号：临 2025-072 | | 被担保人名称 | | 广西九州通医药有限公司、广东九州通 | | --- | --- | --- | --- | | | | 医药有限公司等 | 家子公司 51 | | | 本次担保金额 | 万元 345,350.00 | | | 担保对象 | 实际为其提供的担保余额 | 1,218,734.00 | 万元 | | | 是否在前期预计额度内 | 是 □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额 | 0.00 | | | --- | --- | --- | | （万元） | | | | 截至本公告日上市公司及其 | | | | 控股子公司对外担保总额 | 2,895,749.72 | ...

Report Information - Report Title: Non-ferrous Metals Weekly - Tin [1] - Date: October 21, 2025 [2] - Author: Wang Wenhu [2] - Contact: 021 - 51801878 [2] Investment Rating - Not provided in the report Core View - The uncertainty of China - US tariff negotiations weighs on tin prices, but the expectation of the Fed's future interest rate cuts and halt of balance - sheet reduction, along with the slow resumption of tin mines in Wa State, Myanmar, is unlikely to change the tight supply - demand situation. The Shanghai tin price is expected to be weak first and then strong. Investors are advised to mainly buy on price dips, paying attention to support and resistance levels [3]. Summary by Directory Part 1: Spread and Inventory Situation - The basis of Shanghai tin is positive and the monthly spread is negative, both within a reasonable range. Due to the Fed's future interest rate cut and halt of balance - sheet reduction expectations and the slow resumption of tin mines in Wa State, Myanmar, investors are advised to wait and see for arbitrage opportunities [7][9] - The (0 - 3) contract spread of LME tin is negative and the (3 - 15) contract spread is positive, both within a reasonable range. The Shanghai - London tin price ratio is below the 50% quantile of the past five years. Due to the Fed's expectations and the decreasing inventory of refined tin in LME, investors are advised to wait and see for arbitrage opportunities [10] - The inventory of refined tin in SHFE decreased compared with last week; the social inventory of tin ingots in China decreased compared with last week; the inventory of refined tin in LME increased compared with last week; the total inventory of refined tin at home and abroad decreased compared with last week [12] Part 2: Mid - upstream Supply Situation - The daily processing fee of domestic tin concentrate is oscillating downward, indicating a tight supply expectation of domestic tin mines [18][19] - The production (import) volume of Chinese tin mines in October increased (increased) month - on - month. Factors include the resumption of mines in Myanmar, Indonesia's mine policies, and the situation in other countries [21][23] - The production volume of Chinese recycled tin in October increased month - on - month [24][25] - The capacity utilization rate of Chinese refined tin increased compared with last week. The production (inventory) volume of Chinese refined tin in October increased (decreased) month - on - month [26][28] - The import volume of Chinese refined tin in October may increase month - on - month due to the production plans of foreign mines and export forecasts [29][31] Part 3: Downstream Demand Situation - The daily processing fee of photovoltaic solder strips decreased month - on - month, which may lead to an increase in the capacity utilization rate (inventory) of Chinese tin solder in October [35] - The import (export) volume of Chinese solder strips in October may decrease month - on - month [38][40] - The production (import, export) volume of Chinese tin - plated sheets in October may increase (decrease, decrease) month - on - month [41][43] - The capacity utilization rate of Chinese lead - acid batteries increased compared with last week. As tin is an important additive in lead - acid batteries, this may affect tin demand [44][46]

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Insights - The report indicates a significant rise in the strength of private enterprises in Wuhan, surpassing state-owned enterprises in the number of companies listed in the top 100 rankings for the first time [1] Group 1: R&D Investment - Private enterprises in Wuhan have increased their R&D investment by 54.26% compared to the previous year, significantly outpacing revenue and profit growth [2] - The rise in R&D investment has led to a notable increase in the proportion of invention patents and participation in industry standard formulation [2] - TCL Huaxing's collaboration with Xiaomi on the "Miao Xiang Back Screen" for the Xiaomi 17 Pro series exemplifies the technological advancements being pursued by local companies [2] Group 2: International Expansion - 40 of the top enterprises in Wuhan have begun to expand internationally, transitioning from initial market entry to establishing a local presence [3] - Renfu Pharmaceutical Group has invested in modern pharmaceutical factories in Mali and Ethiopia, resulting in a price reduction of over 30% for certain medications [3] - Longfei Optical Fiber Cable Co., Ltd. has successfully laid the world's first 7-core optical fiber submarine experimental cable, showcasing its technological capabilities on a global scale [3] Group 3: Industry Structure Optimization - The industrial structure of Wuhan's top enterprises is continuously optimizing, with emerging industries becoming key drivers of high-quality development [4] - The integration of AI in logistics by Jiuzhoutong Pharmaceutical Group has significantly enhanced operational efficiency, with an investment of 146 million yuan leading to substantial revenue [4] - Midea Group's investment in smart manufacturing equipment has resulted in over 50% automation in production, demonstrating the impact of technological upgrades [4]

Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Approval - The approval notification for Glycopyrrolate was issued on October 16, 2025 [1] - Glycopyrrolate is indicated for conditions such as gastric and duodenal ulcers, chronic gastritis, and for maintenance treatment in adults with chronic obstructive pulmonary disease (COPD) [1] Group 2: Drug Mechanism and Applications - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The company Kyushu Tong (600998.SH) announced that its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. received approval from the National Medical Products Administration for the marketing application of Glycopyrrolate, a quaternary ammonium anticholinergic drug [1] Group 1: Product Information - Glycopyrrolate selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] - Glycopyrrolate is indicated for the treatment of gastric and duodenal ulcers, chronic gastritis, and for maintenance bronchial dilation therapy in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [1]

证券代码：600998 证券简称：九州通 公告编号：临 2025-071 九州通医药集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 九州通医药集团股份有限公司（以下简称"公司"或"九州通"）控股子公 司北京京丰制药（山东）有限公司（以下简称"山东京丰"）于 2025 年 10 月 16 日收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批 准格隆溴铵上市申请。现将相关情况公告如下： 一、上市申请批准通知书主要信息 化学原料药名称：格隆溴铵 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品其他相关情况 格隆溴铵是一种季铵类抗胆碱药，能选择性作用于消化道，有抑制胃液分泌 和调整胃肠蠕动的作用，也可特异性结合并抑制支气管平滑肌分布的 M3 型乙酰 胆碱受体，扩张气道。该药品可用于胃、十二指肠溃疡及慢性胃炎等，还可用于 成人慢性阻塞性肺疾病（包括慢性支气管炎和肺气肿）患者维持性支气管扩张 ...

九州通公告，控股子公司北京京丰制药（山东）有限公司于2025年10月16日收到国家药品监督管理局核 准签发的《化学原料药上市申请批准通知书》，批准格隆溴铵上市申请。格隆溴铵是一种季铵类抗胆碱 药，能选择性作用于消化道，有抑制胃液分泌和调整胃肠蠕动的作用，也可特异性结合并抑制支气管平 滑肌分布的 M3 型乙酰胆碱受体，扩张气道。格隆溴铵制剂包括格隆溴铵注射液、格隆溴铵吸入粉雾 剂、格隆溴铵吸入溶液、格隆溴铵口服溶液、格隆溴铵片、格隆溴铵福莫特罗吸入气雾剂等多种剂型， 其中格隆溴铵注射液、格隆溴铵福莫特罗吸入气雾剂等已被纳入医保目录。2024年格隆溴铵注射液的医 院销售额达5357.72万元，同比增长38.29%；2025年上半年其医院销售额达3740.7万元，同比增长 79.21%。 ...